Zealand's stock falls 35% after disappointing drug result. Its CEO tells CNBC people need to focus less on the 'weight loss Olympics'

By

Zealand and Roche are jointly developing the drug petrelintide which in a mid-stage study led to a worse-than-expected 10.7% weight-loss over 42 weeks.

Source: Cnbc.com

Original source: https://www.cnbc.com/2026/03/06/zealand-stock-zela-roche-trial-weight-loss-ceo-novo-glp1.html

Post Views: 3

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *